Page last updated: 2024-10-21

3-aminobenzamide and Peritonitis

3-aminobenzamide has been researched along with Peritonitis in 2 studies

Peritonitis: INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.

Research Excerpts

ExcerptRelevanceReference
" In vivo treatment with ip administration of 3-aminobenzamide (10 mg/kg, 1 and 6 hrs after zymosan injection) or nicotinamide (50 mg/kg, 1 and 6 hrs after zymosan injection) significantly decreased mortality, inhibited the development of peritonitis, and reduced peroxynitrite formation."3.70Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat. ( Caputi, AP; Costantino, G; Cuzzocrea, S; Sottile, A; Teti, D; Zingarelli, B, 1999)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Szabó, C1
Lim, LH1
Cuzzocrea, S2
Getting, SJ1
Zingarelli, B2
Flower, RJ1
Salzman, AL1
Perretti, M1
Costantino, G1
Sottile, A1
Teti, D1
Caputi, AP1

Other Studies

2 other studies available for 3-aminobenzamide and Peritonitis

ArticleYear
Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects.
    The Journal of experimental medicine, 1997, Oct-06, Volume: 186, Issue:7

    Topics: Animals; Benzamides; Carrageenan; Cell Movement; Edema; Enzyme Inhibitors; Histocytochemistry; Infla

1997
Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat.
    Critical care medicine, 1999, Volume: 27, Issue:8

    Topics: Animals; Benzamides; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Male; Multip

1999